kr147.30
0.07% day before yesterday
Stockholm, Oct 31, 01:00 pm CET
ISIN
SE0011205202
Symbol
VITR

Vitrolife Stock price

kr147.30
+17.60 13.57% 1M
-10.30 6.54% 6M
-67.70 31.49% YTD
-88.90 37.64% 1Y
-31.30 17.53% 3Y
-66.30 31.04% 5Y
+106.60 261.92% 10Y
+142.54 2,994.54% 20Y
Stockholm, Closing price Fri, Oct 31 2025
+0.10 0.07%
ISIN
SE0011205202
Symbol
VITR
Industry

Key metrics

Basic
Market capitalization
kr19.9b
Enterprise Value
kr20.8b
Net debt
kr893.0m
Cash
kr1.1b
Shares outstanding
135.4m
Valuation (TTM | estimate)
P/E
45.3 | 45.5
P/S
5.7 | 5.6
EV/Sales
5.9 | 5.9
EV/FCF
44.5
P/B
1.5
Dividends
DPS
kr1.10
Yield 1Y | 5Y
0.8% | 0.4%
Growth 1Y | 5Y
10.0% | -
Payout 1Y | 3Y
29.0% | -13.6%
Increased
3 Years
Financials (TTM | estimate)
Revenue
kr3.5b | kr3.6b
EBITDA
kr916.0m | kr1.1b
EBIT
kr657.0m | kr650.0m
Net Income
kr441.0m | kr438.2m
Free Cash Flow
kr468.0m
Growth (TTM | estimate)
Revenue
-1.3% | -1.4%
EBITDA
127.8% | 2.6%
EBIT
118.5% | -17.9%
Net Income
111.6% | -14.6%
Free Cash Flow
-28.6%
Margin (TTM | estimate)
Gross
58.9%
EBITDA
26.1% | 30.4%
EBIT
18.7%
Net
12.6% | 12.3%
Free Cash Flow
13.3%
Financial Health
Equity Ratio
78.2%
Return on Equity
3.8%
ROCE
4.0%
ROIC
3.2%
Debt/Equity
0.2
More
EPS
kr3.3
FCF per Share
kr3.5
Short interest
-
Employees
1k
Rev per Employee
kr3.1m
Show more

Is Vitrolife a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Vitrolife Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Vitrolife forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Vitrolife forecast:

Buy
80%
Hold
20%

Financial data from Vitrolife

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,507 3,507
1% 1%
100%
- Direct Costs 1,441 1,441
3% 3%
41%
2,066 2,066
0% 0%
59%
- Selling and Administrative Expenses 1,033 1,033
4% 4%
29%
- Research and Development Expense 102 102
11% 11%
3%
916 916
128% 128%
26%
- Depreciation and Amortization 259 259
1% 1%
7%
EBIT (Operating Income) EBIT 657 657
118% 118%
19%
Net Profit 441 441
112% 112%
13%

In millions SEK.

Don't miss a Thing! We will send you all news about Vitrolife directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. Its products and services include oocyte retrieval needles, sperm processing, IVF media and oil, micromanipulation pipettes, labware, benchtop incubators, time-lapse systems, preimplantation genetic testing, cryopreservation, laser and imaging systems, and lab quality control systems. The firm operates through the following geographical segments: Europe, Middle East, and Africa (EMEA); North and South America; Japan and Pacific; and Asia. The company was founded in 1994 and is headquartered in Gothenburg, Sweden.

Head office Sweden
CEO Bronwyn O'Connor
Employees 1,150
Founded 1989
Website www.vitrolife.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today